Fierce Biotech News & Reports
Oct 28, 2024 · Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
Mar 19, 2024 · The obesity pipeline: Phase 2 assets. The baselines are already being set. Viking Therapeutics’ dual GLP-1 and GIP agonist produced weight loss of up to 14.7% after 13 weeks of treatment in data ...
Altos bursts out of stealth with $3B, a dream team C-suite and a …
Jan 19, 2022 · Altos Labs just redefined big. RELATED: Barron quits GSK to take CEO post at $3B biotech startup The team will use $3 billion in capital committed by investors including Arch Venture Partners to ...
BMS signs $674M biobucks pact with VantAI for molecular glues
Feb 13, 2024 · Bristol Myers Squibb is offering Roivant-backed VantAI up to $674 million biobucks in a new partnership aimed at designing molecular glues as small-molecule therapeutics.. The Big Pharma wants in ...
Biotech | Fierce Biotech
Oct 28, 2024 · Kymera pivots to immunology, seeks partners for cancer assets. Kymera is pivoting to immunology, with plans to only develop cancer programs beyond phase 1 through partnerships. Gabrielle Masson ...
FDA OKs Neuralace’s nerve stimulation tech for diabetes pain
Jan 11, 2024 · In mid-2021, after a decade of R&D, Neuralace Medical earned FDA clearance for its Axon Therapy, a noninvasive treatment option for chronic pain caused by nerve damage. The road to its next ...
Vertex meets own cystic fibrosis record with next-gen treatment
Feb 5, 2024 · UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta. By Gabrielle Masson Feb 5, 2024 7:50pm. Vertex Pharmaceuticals cystic fibrosis Trikafta FDA. New ...
3 years after rejecting $1B buyout, Sorrento files for bankruptcy …
Feb 13, 2023 · Sorrento contends that Soon-Shiong originally suggested that Celgene buy the generic rival, called Cynviloq, but that the larger pharma rejected the proposal on the grounds that it would likely ...
Immunome pays $50M for Ayala's phase 3 desmoid tumor drug
Feb 6, 2024 · Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks. By James Waldron Feb 6, 2024 9:50am. Immunome Licensing deals Ayala Pharmaceuticals tumors. Should AL102 live ...
Next-gen Lilly obesity drug secures first ph. 3 win for Innovent
Jan 9, 2024 · Next-gen Lilly obesity drug secures phase 3 win as Innovent readies Chinese approval push. By James Waldron Jan 9, 2024 5:29am. Eli Lilly Innovent Biologics Obesity GLP-1. The drug’s safety ...